A Phase 3b Open-Label Study of Long-Term Neurocognitive Outcomes in Children With Phenylketonuria Treated With Sepiapterin
PTC Therapeutics
Summary
The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functioning in children with PKU when treatment is initiated in early childhood.
Description
The study includes 2 parts: Part 1 and 2. Part 1 is an open-label sepiapterin-responsiveness test and Part 2 is an open-label treatment period.
Eligibility
- Age range
- Up to 9 years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria: For all participants: * Women of childbearing potential must have a negative pregnancy test at Screening and agree to abstinence or the use of at least one highly effective form of contraception for the duration of the study, and for at least 90 days after the last dose of the study drug. * Willing to maintain prescribed daily protein/Phe during Screening and Part 1. For participants ≥1 month of age at Screening: * Established diagnosis of PKU with hyperphenylalaninemia (HPA) evidenced by at least 2 blood Phe measurement ≥600 micromoles (μmol)/liter (L) as documente…
Interventions
- DrugSepiapterin
Sepiapterin powder for oral use will be mixed in water or apple juice prior to administration.
Locations (8)
- Indiana University School of MedicineIndianapolis, Indiana
- Women and Children HospitalNorth Adelaide
- The Royal Children's HospitalParkville
- Centre Hospitalier Régional Universitaire (CHRU) de Tours - Hôpital ClochevilleTours
- Children's Health Ireland (CHI)Dublin
- Pomorski Uniwersytet Medyczny w SzczecinieSzczecin